# Translational Oncology Research Program

> **NIH NIH P30** · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $57,360

## Abstract

PROJECT SUMMARY: Translational Oncology Research Program
Jeffrey W. Tyner, Ph.D., and Lara Davis, M.D., Program Co-Leaders
The goal of the Translational Oncology (TO) Program is to translate cutting-edge biology into high-impact
interventions, with the aim of improving outcomes for patients with cancer. TO serves as the translational engine
of the Knight Cancer Institute (KCI), collaborating with members of all KCI Programs to translate their findings
into clinical investigations to benefit patients and advance understanding of the disease. TO research is
organized into two themes 1) Target Validation and 2) High-Impact Interventions that align with and directly
support the KCI Strategic Plan's foundations of Precision Early Detection and Precision Oncology. TO is a
transdisciplinary program comprising 70 members from 18 departments, divisions, and institutes at OHSU. TO
members produced 1,286 publications, of which 23% were intra-programmatic, 28% inter-programmatic and
70% inter-institutional collaborations. Total direct cost funding as of December 31, 2020 was $24,777,777, with
peer-reviewed funding of $4,929,404 and $2,833,122 or 57% being from the NCI. TO activities, often in
collaboration with other KCI Programs, have led to paradigm- and practice-changing impact across numerous
catchment area priority cancers. These include the largest-to-date integrative multi-omic cancer dataset, which
has been leveraged into cutting-edge clinical trials and is used by researchers around the world (Beat AML).
Numerous practice-changing therapeutics, originating from collaborative, trans-programmatic discoveries, have
been validated in pivotal trials in leukemia, sarcoma, and prostate cancer. The development of transformational
platforms has enabled real-time allocation of novel combination therapies in a cancer-agnostic manner based
on broad and deep tumor analytics conducted in a CLIA-approved environment. TO investigators also conducted
clinical trials leading to the first-ever demonstration of drug class activity in specific cancer types (e.g., checkpoint
blockade in prostate cancer). TO activities spearheaded precision early detection trials of non-invasive
technologies with exquisite sensitivity that facilitate diagnosis, monitoring, and follow-up. These and other TO
accomplishments engage the community and catchment area in a bidirectional manner where transformational
research and novel therapies are made available to the community while patient and advocate engagement
helps shape and inform research strategies. These activities also offer numerous opportunities for the education
and training of the next generation of scientists and physician-researchers. The TO Program plans to build on
the success of these existing projects with new endeavors, such as the Center for Experimental Therapeutics,
which will provide a resource for drug development and rapid translation into clinical trials.

## Key facts

- **NIH application ID:** 10891358
- **Project number:** 5P30CA069533-26
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** Jeffrey Wallace Tyner
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $57,360
- **Award type:** 5
- **Project period:** 1997-08-01 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10891358

## Citation

> US National Institutes of Health, RePORTER application 10891358, Translational Oncology Research Program (5P30CA069533-26). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10891358. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*